Clinical Trial

FMXIN002 in Patients at Risk of Anaphylaxis

Enrolling by Invitation Phase 2/3
View on ClinicalTrials.gov →
Record status
This record was last updated July 1, 2025 (before its estimated June 12, 2026 completion). Its status may not reflect the trial's current state.
Summary
Study Objective To evaluate the efficacy of FMXIN002, a powder-based intranasal epinephrine spray, for treating anaphylaxis. Study Design • Hypothesis: FMXIN002 will terminate anaphylactic reactions as effectively-or more rapidly-than IM epinephrine, as measured by clinical parameters.
Trial Details
NCT Number NCT07045701
Lead Sponsor Nasus Pharma
Conditions Anaphylaxis Food
Enrollment 30 participants
Start Date 2025-06-12
Primary Completion 2026-06-12 (estimated)
Study Completion 2026-07-12 (estimated)
Updated on ClinicalTrials.gov 2025-07-01